AgingResearch.NewsJoin free

Fidaxomicin

Fidaxomicin has been studied in 2 papers since 2024: 2 observational studies in people. The newest paper, Aug 8, 2025: “The role of Frailty Index Laboratory in predicting clinical outcomes in patients with Clostridioides difficile infections: a 2020-24 single-centre retrospective study”.

Intervention

2 papers study it1 more mentions it1 findingUpdated

PubChem

See all 3

“Fidaxomicin use did not significantly reduce mortality or recurrence after adjustment for FI-Lab and comorbidities.”
The role of Frailty Index Laboratory in predicting clinical outcomes in patients with Clostridioides difficile infections: a 2020-24 single-centre retrospective studyJAC-antimicrobial resistance2025doi:10.1093/jacamr/dlaf143

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Humans2

What did studies of Fidaxomicin find?

1

Studies of Fidaxomicin measured 1 outcome; the most studied are mortality (1 study).

Mortality

no changein humans1

1 study

  1. Fidaxomicin has no effect on mortality in humans.

    “Fidaxomicin use did not significantly reduce mortality or recurrence after adjustment for FI-Lab and comorbidities.”

    Humansafter adjustment for FI-Lab and comorbidities in CDI hospitalized patientsn = 280

    The role of Frailty Index Laboratory in predicting clinical outcomes in patients with Clostridioides difficile infections: a 2020-24 single-centre retrospective study

    JAC-antimicrobial resistance

Latest

Related